SEC Form 4 · accession 0000899243-18-001062
GYRE THERAPEUTICS, INC. · GYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Howard Levy
Officer — Chief Medical Officer
Period of report
Jan 12, 2018
Accepted (ET)
Jan 16, 2018 · 3:42 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001124105
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option(Right to Buy)F1 | $15.13 | Jan 12, 2018 | A | 33,000 | A | — | Jan 12, 2028 | Common Stock | 33,000 | 33,000 | D |
Explanation of responses
- F1The Option vests monthly over a period of four years commencing January 12, 2018.